|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Measurements of dihadron correlations relative to the event plane in Au+Au collisions at√^(S)NN=200 GeV显示文摘Dihadron azimuthal correlations containing a high transverse momentum(pr)trigger particle are sensit-ive to the properties of the nuclear medium created at RHIC through the strong interactions occurring between the traversing parton and the medium,ie.jet-quenching.Previous measurements revealed a strong modification to di-hadron azimuthal correlations in Au+Au collisions with respect to ptp and d+Au collisions.The modification in-creases with the collision centrality,suggesting a path-length or energy density dependence to the je-quenching ef-fect.This paper reports STAR measurements of dihadron azimuthal correlations in mid-central(20%-60%)Au+Au collisions at√^(S)NN=200 GeV as a function of the trigger particle's azimuthal angle relative to the event plane,Ф_(s)=|Ф_(t)-ψ_(Ep)|.The azimuthal correlation is studied as a function of both the trigger and associated particle pr.The subtractions of the combinatorial background and anisotropic flow,assuming Zero Yield At Minimum(ZYAM),are described.The correlation results are first discussed with subtraction of the even harmonic(elliptic and quadrangu-lar)flow backgrounds.The away-side correlation is strongly modifed,and the modification varies withФ_(s),with a double-peak structure for out-of-plane trigger particles.The near-side ridge(long range pseudo-rapidity△_(η)correla-tion)appears to drop with increasingФ_(s)while the jet-like component remains approximately constant.The correla-tion functions are further studied with the subtraction of odd harmonic triangular flow background arising from fluc-tuations.It is found that the triangular flow,while responsible for the majority of the amplitudes,is not sufficient to explain theφs-dependence of the ridge or the away-side double-peak structure.The dropping ridge withФ_(s)could be attributed to aФ_(s)-dependent lliptie anisotropy;however,the physics mechanism of the ridge remains an open ques-tion.Even with aФ_(s)-dependent elliptic flow,the away-side correlation structure is robust.These results,with extens-ive systematic studies of the dihadron correlations as a function ofФ_(s),trigger and associated particle pT,and the pseudo-rapidity range△_(η),should provide stringent inputs to help understand the underlying physics mechanisms of jet-medium interactions in high energy nuclear collisions. | H.Agakishiev M.M.Aggarwal Z.Ahammed A.V.Alakhverdyants I.Alekseev J.Alford B.D.Anderson C.D.Anson D.Arkhipkin G.S.Averichev J.Balewski D.R.Beavis N.K.Behera R.Bellwied M.J.Betancourt R.R.Betts A.Bhasin A.K.Bhat H.Bichsel J.Bieleik J.Bielcikova B.Biritz L.C.Bland W.Borowski J.Bouchet E.Braidot A.V.Brandin A.Bridgeman S.G.Brovko E.Bruna S.Bueltmann I.Bunzarov T.P.Burton X.Z.Cai H.Caines M.Calderon de la Barca Sanchez D.Cebra R.Cendejas M.C.Cervantes Z.Chajecki P.Chaloupka S.Chattopadhyay H.F.Chen J.H.Chen J.Y.Chen L.Chen J.Cheng M.Cherney A.Chikanian K.E.Choi W.Christie P.Chung M.J.M.Codrington R.Corliss J.G.Cramer H.J.Crawford S.Dash A.Davila Leyva L.C.De Silvat R.R.Debbe T.G.Dedovich A.A.Derevschikov R.Derradi de Souza L.Didenko P.Djawotho S.M.Dogra X.Dong J.L.Drachenberg J.E.Draper J.C.Dunlop L.G Efimov M.Elnim J.Engelage G Eppley M.Estienne L.Eun O.Evdokimov R.Fatemi J.Fedorisin A.Feng R.G.Fersch P.Filip E.Finch V.Fine Y.Fisyak C.A.Gagliardi D.R.Gangadharan A.Geromitsos F.Geurts P.Ghosh Y.N.Gorbunov A.Gordon O.Grebenyuk D.Grosnick S.M.Guertin A.Gupta W.Guryn B.Haag O.Hajkova A.Hamed L-X.Han J.W.Harris J.P.Hays-Wehle M.Heinz S.Heppelmann A.Hirsch E.Hjort G.W.Hoffmann D.J.Hofiman B.Huang H.Z.Huang T.J.Humanic L.Huo G.Igo P.Jacobs W.W.Jacobs C.Jena F.Jin J.Joseph E.G.Judd S.Kabana K.Kang J.Kapitan K.Kauder H.Ke D.Keane A.Kechechyan D.Kettler D.P.Kikola J.Kiryluk A.Kisiel V.Kizka A.G.Knospe D.D.Koetke T.Kollegger J.Konzer I.Koralt L.Koroleva W.Korsch L.Kotchenda V.Kouchpil P.Kravtsov K.Krueger M.Krus L.Kumar P.Kurnadi M.A.C.Lamont J.M.Landgraf S.LaPointe J.Lauret A.Lebedev R.Lednicky J.H.Lee W.Leight M.J.LeVine C.Lil L.Li N.Li W.Li X.Li X.Li Y.Li Z.M.Li M.A.Lisa F.Liu H.Liu J.Liu T.Ljubicic W.J.Llope R.S.Longacre W.A.Love Y.Lu E.V.Lukashov X.Luo G.L.Ma Y.G.Mai D.P.Mahapatra R.Majka O.I.Mall L.K.Mangotra R.Manweiler S.Margetis C.Markert H.Masui H.S.Matis Yu.A.Matulenko D.MeDonald T.S.McShane A.Meschanin R.Milner N.G.Minaev S.Mioduszewski A.Mischke M.K.Mitrovski B.Mohanty M.M.Mondal B.Morozov D.A.Morozov M.G.Munhoz M.Naglis B.K.Nandi T.K.Nayak P.K.Netrakanti L.V.Nogach S.B.Nurushev G.Odyniec A.Ogawa Oh Ohlson V.Okorokov E.W.Oldag D.Olsont M.Pachr B.S.Page S.K.Pal Y.Pandit Y.Panebratsev T.Pawlak H.Pei T.Peitzmann C.Perkins W.Peryt S.C.Phatak P.Pile M.Planinic M.A.Ploskon J.Pluta D.Plyku N.Poljak A.M.Poskanzer B.V.K.S.Potukuchi C.B.Powell D.Prindle N.K.Pruthi A.M.Poskanzer B.V.K.S.Potukuchi B.Powell D.Prindle N.K.Pruthi P.R.Pujahar J.Putschke H.Qiu R.Raniwala S.Raniwala R.L.Ray R.Redwine R.Reed H.G.Riter J.B.Roberts O.V.Rogachevskiy J.L.Romero A.Rose L.Ruan J.Rusnak N.R.Sahoo S.Sakai I.Sakrejda T.Sakuma S.Salur J.Sandweiss E.Sangaline A.Sarkar J.Schambach R.P.Scharenberg A.M.Schmah N.Schmitz T.R.Schuster J.Seele J.Seger I.Selyuzhenkov P.Seyboth E.Shahaliev M.Shao M.Sharma S.S.Shi Q.Y.Shou E.P.Sichtermann F.Simon R.N.Singaraju M.J.Skoby N.Smirnov H.M.Spinka B.Srivastava T.D.S.Stanislaus D.Staszak S.G.Steadman J.R.Stevens R.Stock M.Strikhanov B.Stringfellow A.A.P.Suaide M.C.Suarez N.L.Subba M.Sumbera X.M.Sun Y.Sun Z.Sun B.Surrow D.N.Svirida T.J.M.Symons A.Szanto de Toledo J.Takahashi A.H.Tang Z.Tang L.H.Tarini T.Tarnowsky D.Thein J.H.Thomas J.Tian A.R.Timmins D.Tlusty M.Tokarev V.N.Tram S.Trentalange R.E.Tribble Tribedy O.D.Tsai T.Ullrich D.G.Underwood G.Van Buren G.van Nieuwenhuizen J.A.Vanfossen R.Varma G.M.S.Vasconcelos A.N.Vasiliev F.Videbaek Y.P.Viyogi S.Vokal M.Wadat M.Walker F.Wang G.Wang H.Wang J.S.Wang Q.Wang X.L.Wang Y.Wang G.Webb J.C.Webb G.D.Westfall C.Whitten H.Wieman S.W.Wissink R.Witt W.Witzke Y.F.Wu Xiao W.Xie H.Xu N.Xu Q.H.Xu W.Xu Y.Xu Z.Xu L.Xue Y.Yang P.Yepes K.Yip I-K.Yoo M.Zawisza H.Zbroszczyk W.Zhan J.B.Zhang S.Zhang W.M.Zhang X.P.Zhang Y.Zhang Z.P.Zhang J.Zhao C.Zhong W.Zhou X.Zhu Y.H.Zhu R.Zoulkarneev Y.Zoulkarneeva | 2021 | Chinese Physics C2021，45，4： | 351 |
| 2 | Pathophysiological 角色和在糖尿病的 nephropathy 的发炎的治疗学的含意显示文摘 Diabetes mellitus and its complications are becoming one of the most important health problems in the world. Diabetic nephropathy is now the main cause of end-stage renal disease. The mechanisms leading tothe development and progression of renal injury are not well known. Therefore, it is very important to f ind new pathogenic pathways to provide opportunities for early diagnosis and targets for novel treatments. At the present time, we know that activation of innate immunity with development of a chronic low grade inflammatory response is a recognized factor in the pathogenesis of diabetic nephropathy. Numerous experimental and clinical studies have shown the participation of different inflammatory molecules and pathways in the pathophysiology of this complication. | Desirée Luis-Rodríguez Alberto Martínez-Castelao José Luis Górriz Fernando de lvaro Juan F Navarro-González | 2012 | World Journal of Diabetes2012，3，1： | 55 |
| 3 | Fecal microbiota transplantation as novel therapy in gastroenterology:A systematic review显示文摘AIM:To study the clinical efficacy and safety of Fecal microbiota transplantation(FMT).We systematically reviewed FMT used as clinical therapy.METHODS:We searched MEDLINE,EMBASE,the Cochrane Library and Conference proceedings from inception to July,2013.Treatment effect of FMT was calculated as the percentage of patients who achieved clinical improvement per patient category,on an intention-to-treat basis.RESULTS:We included 45 studies;34 on Clostridium difficile-infection(CDI),7 on inflammatory bowel disease,1 on metabolic syndrome,1 on constipation,1 on pouchitis and 1 on irritable bowel syndrome(IBS).In CDI 90% resolution of diarrhea in 33 case series(n = 867) was reported,and 94% resolution of diarrhea after repeated FMT in a randomized controlled trial(RCT)(n = 16).In ulcerative colitis(UC) remission rates of 0% to 68% were found(n = 106).In Crohn's disease(CD)(n = 6),no benefit was observed.In IBS,70% improvement of symptoms was found(n = 13).100% Reversal of symptoms was observed in constipation(n = 3).In pouchitis,none of the patients(n = 8) achieved remission.One RCT showed significant improvement of insulin sensitivity in metabolic syndrome(n = 10).Serious adverse events were rare.CONCLUSION:FMT is highly effective in CDI,and holds promise in UC.As for CD,chronic constipation,pouchitis and IBS data are too limited to draw conclusions.FMT increases insulin sensitivity in metabolic syndrome. | Noortje G Rossen John K Mac Donald Elisabeth M de Vries Geert R D'Haens Willem M de Vos Erwin G Zoetendal Cyriel Y Ponsioen | 2015 | World Journal of Gastroenterology2015，21，17： | 41 |
| 4 | 帕博利珠单抗单用或与放疗联用治疗转移性非小细胞肺癌:两个随机试验的汇总分析显示文摘背景放疗可以提高整个机体对免疫治疗的应答。在Ⅱ期PEMBRO-RT研究和Ⅰ/Ⅱ期MDACC研究中,患有转移性非小细胞肺癌(NSCLC)的患者被随机分配入组,接受免疫治疗(帕博利珠单抗)+放疗联合疗法,或免疫治疗单一疗法。当上述2个研究单独分析时,联合疗法组显示出潜在获益。由于每个研究的样本量较小,缓解率和结局并未显示出统计学意义,然而却有显著的临床获益。因此,本研究进行汇总分析,来判断放疗是否会改善转移性NSCLC患者的免疫治疗应答。方法PEMBRO-RT和MDACC研究纳入标准:患者年龄≥18岁,患有转移性NSCLC,且有≥1处未经放疗照射的病灶,以便进行射野外应答监测。PEMBRO-RT研究纳入曾接受过化疗患者,MDACC研究纳入曾接受过治疗或新诊断患者。2个研究中的患者均未接受过免疫治疗。在PEMBRO-RT研究中患者被等比例随机分配入组,并根据吸烟状态进行分层(分为<10年组和≥10年组)。MDACC研究的患者根据放疗计划可行性被等比例随机分配入2个受试组。由于联合治疗组的干预本质,每个研究中的放疗均不适用盲法。在2个研究中,不论是否进行放疗,均静脉滴入帕博利珠单抗(每3周200 mg)。在PEMBRO-RT研究中,在放疗(24 Gy 3次分割照射)结束后1周给予第1剂帕博利珠单抗。在MDACC研究中,在第1次放疗(50 Gy 4次分割照射或45 Gy 15次分割照射)同时给予帕博利珠单抗。仅检测未经照射病灶的应答。本研究的终点为最佳射野外(远隔)应答率(ARR)、最佳射野外疾病控制率(ACR)、12周时ARR、12周时ACR、无进展生存期(PFS)和总生存期(OS)。2个研究的意向治疗(ITT)人群均纳入分析。PEMBRO-RT研究(NCT02492568)和MDACC研究(NCT02444741)均在ClinicalTrials.gov上注册。发现纳入148例患者,76例接受帕博利珠单抗治疗,72例接受帕博利珠单抗+放疗治疗。所有患者随访时间中位数为33个月[四分位距(IQR):32.4~33.6]。148例患者中124例(84%)组织学特征为非鳞癌,111例(75%)患者曾经接受过化疗。组间没有基线特征差异,包括PD-L1表达状态和转移灶体积。最常见的照射部位为肺转移灶(39%,28/72)、胸腔内淋巴结(21%,15/72)和非原发灶(17%,12/72)。帕博利珠单抗组和联合治疗组的最佳ARR分别为19.7%(15/76)和41.7%(30/72),OR=2.96,95%CI:1.42~6.20,P=0.0039;最佳ACR分别为43.4%(33/76)和65.3%(47/72),OR=2.51,95%CI:1.28~4.91,P=0.0071;PFS中位数分别为4.4(IQR:2.9~5.9)和9.0个月(IQR:6.8~11.2),HR=0.67,95%CI:0.45~0.99,P=0.045;OS中位数分别为8.7(IQR:6.4~11.0)和19.2个月(IQR:14.6~23.8),OR=0.67,95%CI:0.54~0.84,P=0.0004。在汇总分析中没有发现新的安全问题。解读帕博利珠单抗免疫疗法+放疗显著提高转移性NSCLC患者的应答和改善治疗结局。这些结果需要在三期临床试验中进行验证。 | 陈大卫(翻译) 于金明(校对) Willemijn S M E Theelen Vivek Verma Brian P Hobbs Heike M U Peulen Joachim G J V Aerts Idris Bahce Anna Larissa N Niemeijer Joe Y Chang Patricia M de Groot Quynh-Nhu Nguyen Nathan I Comeaux George R Simon Ferdinandos Skoulidis Steven H Lin Kewen He Roshal Patel John Heymach Paul Baas James W Welsh | 2021 | 中华肿瘤防治杂志2021，28，24： | 49 |
| 5 | MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells显示文摘 | Godlewski J Nowicki MO Bronisz A Nuovo G Palatini J De Lay M Van Brocklyn J Ostrowskl MC Chlocca EA Lawler SE. | 2010 | 中国神经肿瘤杂志2010，8，1： | 37 |
| 6 | 最新AD研究用诊断标准:IWG-2标准显示文摘在过去的8年中,国际工作组织(IWG)和美国国立老化研究院-阿尔茨海默协会(NIA-AA)建立了阿尔茨海默病(AD)诊断标准,它能更好地定义AD的临床表型,整合了生物标记物于诊断流程中,并覆盖了疾病的全程。本意见书充分地权衡了IWG标准的优缺点,建议改进诊断框架。依据这些改进,AD的诊断变得简单,只要有恰当的AD临床表型(典型或不典型)和与AD的病理相一致的病理生理学生物标志物出现。我们认为疾病的下游的定位性生物标志,如容积性磁共振成像(MRI)和氟脱氧葡萄糖-正电子发射型计算机断层成像(FDG-PET)等,适合更好地测量和监测疾病过程。本文还详述了非典型性AD、混合性AD和AD临床前期的特异诊断标准。 | 陈刚 曹雯炜 俞羚 糜建华 Dubois B Feldman HH Jacova C Hampel H Molinuevo JL Blennow K DeK osky ST Gauthier S Selkoe D Bateman R Cappa S Crutch S Engelborghs S Frisoni GB Fox NC Galasko D Habert MO Jicha GA Nordberg A Pasquier F Rabinovici G Robert P Rowe C Salloway S Sarazin M Epelbaum S de Souza LC Vellas B Visser PJ Schneider L Stern Y Scheltens P Cummings JL | 2014 | 神经病学与神经康复学杂志2014，11，3： | 31 |
| 7 | Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis显示文摘The pool of microbes inhabiting our body is known as 'microbiota' and their collective genomes as 'microbiome'. The colon is the most densely populated organ in the human body, although other parts, such as the skin, vaginal mucosa, or respiratory tract, also harbour specific microbiota. This microbial community regulates some important metabolic and physiological functions of the host, and drives the maturation of the immune system in early life, contributing to its homeostasis during life. Alterations of the intestinal microbiota can occur by changes in composition(dysbiosis), function, or microbiota-host interactions and they can be directly correlated with several diseases. The only disease in which a clear causal role of a dysbiotic microbiota has been demonstrated is the case of Clostridium difficile infections. Nonetheless, alterations in composition and function of the microbiota have been associated with several gastrointestinal diseases(inflammatory bowel disease, colorectal cancer, or irritable bowel syndrome), as well as extra-intestinal pathologies, such as those affecting the liver, or the respiratory tract(e.g., allergy, bronchial asthma, and cystic fibrosis), among others. Species of Bifidobacterium genus are the normal inhabitants of a healthy human gut and alterations in number and composition of their populations is one of the most frequent features present in these diseases. The use of probiotics, including bifidobacteria strains, in preventive medicine to maintain a healthy intestinal function is well documented. Probiotics are also proposed as therapeutic agents for gastrointestinal disorders and other pathologies. The World Gastroenterology Organization recently published potential clinical applications for several probiotic formulations, in which species of lactobacilli are predominant. This review is focused on probiotic preparations containing Bifidobacterium strains, alone or in combination with other bacteria, which have been tested in human clinical studies. In spite of extensive literature on and research into this topic, the degree of scientific evidence of the effectiveness of probiotics is still insufficient in most cases. More effort need to be made to design and conduct accurate human studies demonstrating the efficacy of probiotics in the prevention, alleviation, or treatment of different pathologies. | Rafael Tojo Adolfo Suárez Marta G Clemente Clara G de los Reyes-Gavilán Abelardo Margolles Miguel Gueimonde Patricia Ruas-Madiedo | 2014 | World Journal of Gastroenterology2014，20，41： | 33 |
| 8 | Use of probiotics for prevention of radiation-induced diarrhea显示文摘AIM: To investigate the efficacy of a high-potency probiotic preparation on prevention of radiation-induced diarrhea in cancer patients. METHODS: This was a double-blind, placebo-controlled trial. Four hundred and ninety patients who underwent adjuvant postoperative radiation therapy after surgery for sigmoid, rectal, or cervical cancer were assigned to either the high-potency probiotic preparation VSL#3 (one sachet t.i.d.,) or placebo starting from the first day of radiation therapy. Efficacy endpoints were incidence and severity of radiation-induced diarrhea, daily number of bowel movements, and the time from the start of the study to the use of loperamide as rescue medication. RESULTS: More placebo patients had radiation-induced diarrhea than VSL#3 patients (124 of 239 patients, 51.8%, and 77 of 243 patients, 31.6%; P < 0.001) and more patients given placebo suffered grade 3 or 4 diarrhea compared with VSL#3 recipients (55.4% and 1.4%, P < 0.001). Daily bowel movements were 14.7 ± 6 and 5.1 ± 3 among placebo and VSL#3 recipients (P < 0.05), and the mean time to the use of loperamide was 86 ± 6 h for placebo patients and 122 ± 8 h for VSL#3 patients (P < 0.001). CONCLUSION: Probiotic lactic acid-producing bacteria are an easy, safe, and feasible approach to protect cancer patients against the risk of radiation-induced diarrhea. | P Delia G Sansotta V Donato P Frosina G Messina C De Renzis G Famularo | 2007 | World Journal of Gastroenterology2007，13，6： | 29 |
| 9 | Modern management of rectal cancer: A 2006 update显示文摘The goal of this review is to outline some of the important surgical issues surrounding the management of patients with early (T1/T2 and NO), as well as locally advanced (T3/T4 and/or N1) rectal cancer. Surgery for rectal cancer continues to develop towards the ultimate goals of improved local control and overall survival, maintaining quality of life, and preserving sphincter, genitourinary, and sexual function. Information concerning the depth of tumor penetration through the rectal wall, lymph node involvement, and presence of distant metastatic disease is of crucial importance when planning a curative rectal cancer resection. Preoperative staging is used to determine the indication for neoadjuvant therapy as well as the indication for local excision versus radical cancer resection. Local excision is likely to be curative in most patients with a primary tumor which is limited to the submucosa (T1N0M0), without high-risk features and in the absence of metastatic disease. In appropriate patients, minimally invasive procedures, such as local excision, TEM, and laparoscopic resection allow for improved patient comfort, shorter hospital stays, and earlier return to preoperative activity level. Once the tumor invades the muscularis propria (T2), radical rectal resection in acceptable operative candidates is recommended. In patients with transmural and/or node positive disease (T3/T4 and/or N1) with no distant metastases, preoperative chemoradiation followed by radical resection according to the principles of TME has become widely accepted. During the planning and conduct of a radical operation for a locally advanced rectal cancer, a number of surgical management issues are considered, including: (1) total mesorectal excision (TME); (2) autonomic nerve preservation (ANP); (3) circumferential resection margin (CRM); (4) distal resection margin; (5) sphincter preservation and options for restoration of bowel continuity; (6) laparoscopic approaches; and (7) postoperative quality of life. | Glen C Balch Alex De Meo Jose G Guillem | 2006 | World Journal of Gastroenterology2006，12，20： | 26 |
| 10 | Interplay between inflammation,immune system and neuronal pathways:Effect on gastrointestinal motility显示文摘Sepsis is a systemic inflammatory response representing the leading cause of death in critically ill patients,mostly due to multiple organ failure.The gastrointestinal tract plays a pivotal role in the pathogenesis of sepsisinduced multiple organ failure through intestinal barrier dysfunction,bacterial translocation and ileus.In this review we address the role of the gastrointestinal tract,the mediators,cell types and transduction pathways involved,based on experimental data obtained from models of inflammation-induced ileus and (preliminary) clinical data.The complex interplay within the gastrointestinal wall between mast cells,residential macrophages and glial cells on the one hand,and neurons and smooth muscle cells on the other hand,involves intracellular signaling pathways,Toll-like receptors and a plethora of neuroactive substances such as nitric oxide,prostaglandins,cytokines,chemokines,growth factors,tryptases and hormones.Multidirectional signaling between the different components in the gastrointestinal wall,the spinal cord and central nervous system impacts inflammation and its consequences.We propose that novel therapeutic strategies should target inflammation on the one hand and gastrointestinal motility,gas-trointestinal sensitivity and even pain signaling on the other hand,for instance by impeding afferent neuronal signaling,by activation of the vagal anti-inflammatory pathway or by the use of pharmacological agents such as ghrelin and ghrelin agonists or drugs interfering with the endocannabinoid system. | Benedicte Y De Winter Joris G De Man | 2010 | World Journal of Gastroenterology2010，16，44： | 23 |
| 11 | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?显示文摘Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC. | Giorgia Marisi Alessandro Cucchetti Paola Ulivi Matteo Canale Giuseppe Cabibbo Leonardo Solaini Francesco G Foschi Serena De Matteis Giorgio Ercolani Martina Valgiusti Giovanni L Frassineti Mario Scartozzi Andrea Casadei Gardini | 2018 | World Journal of Gastroenterology2018，24，36： | 14 |
| 12 | [^11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence显示文摘 | Ceyssens S Van Laere K de Groot T Goffin J Bormans G Mortelmans L | 2006 | 中国神经肿瘤杂志2006，4，3： | 13 |
| 13 | Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population显示文摘● AIM: To assess if the included vascular endothelial growth factor(VEGF) polymorphisms rs3025035, rs3025021 and rs2010963 are associated to proliferative retinopathy in a Mexican population with type 2 diabetes mellitus(T2DM).● METHODS: A case-control study was conducted in adult individuals with T2 DM associated to proliferative retinopathy or non-proliferative retinopathy from Oct. 2014 to Jun. 2015 from the Retina Department of the Asociation to Prevent Blindness in Mexico. The selected patients were adults with a diagnosis of T2 DM ≥5y. All subjects had a comprehensive ocular examination and the classification of the retinopathy severity was made considering the Early Treatment Diabetic Retinopathy Study(ETDRS) standardization protocols. Genomic DNA was extracted from whole fresh blood. All samples were genotyped by q PCR for selected VEGF polymorphisms. Hardy-Weinberg equilibrium was calculated by comparing Chi-square values between the expected and the observed values for genotype counts.● RESULTS: In total 142 individuals were enrolled, 71 individuals with T2 DM and associated proliferative retinopathy and 71 individuals with non-proliferative retinopathy. One-sided Fisher's exact test was performed for rs3025021[OR(95% CI)=0.44(0.08-2.2); P=0.25] and rs2010963 [OR(95% CI)=0.63(0.25-1.6); P=0.23]. The minor allelic frequencies obtained were 26% for rs3025021, 10% for rs3025035 and 61% for rs2010963. The pairwise linkage disequilibrium between the three SNP was assessed, and was as follows: rs3025021 vs rs3025035: D'=1.0, r^2=0.1043, P≤0.0001; rs3025021 vs rs2010963: D'=0.442, r^2=0.0446, P=0.149; rs3025035 vs rs2010963: D'=0.505, r^2=0.0214, P=0.142.● CONCLUSION: This is the first analysis involving VEGFA polymorphisms and proliferative diabetic retinopathy in a Mexican population. A major finding of the present study is that none of the polymorphisms studied was significantly associated with proliferative retinopathy. Based on these results, we can infer that different populations have different associations for the same polymorphisms. | Roberto Gonzalez-Salinas Maria C Garcia-Gutierrez Gerardo Garcia-Aguirre Virgilio Morales-Canton Raul Velez-Montoya Vidal R Soberon-Ventura Victoria Gonzalez Rodrigo Lechuga Pablo Garcia-Solis David G Garcia-Gutierrez Marco Vinicio Garcia-Solis Manuel Saenz de Viteri Juan C Solis-S | 2017 | International Journal of Ophthalmology(English edition)2017，10，1： | 12 |
| 14 | Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine显示文摘AIM: To investigate the reduction in hepatitis B virus(HBV) covalently closed-circular DNA(ccc DNA) with entecavir(ETV) or lamivudine(LAM). METHODS: This analysis included patients who had participated in the randomized Phase Ⅲ study ETV-022 comparing ETV vs LAM in nucleos(t)ide-naive, HBe Agpositive patients. Patients received ETV(0.5 mg daily) or LAM(100 mg daily) for a minimum of 52 wk. Patients were eligible to participate in this sub-study if they had paired biopsies at baseline and week 48 with evaluable measurements for hepatic HBV ccc DNA and total hepatic HBV DNA. The main objective was to compare changes in hepatic HBV ccc DNA and total hepatic HBV DNA at week 48 of ETV or LAM treatment, which was a secondary endpoint of study ETV-022. Additional post hoc analyses included linear regression analyses to assess associations of baseline levels and on-treatment changes of ccc DNA with other baseline factors [sex,age, serum HBV DNA, alanine aminotransferase(ALT), Knodell necroinflammatory score, Ishak fibrosis score, total hepatic HBV DNA, and HBV genotype], or ontreatment factors(changes from baseline at week 48 in serum HBV DNA, ALT, Knodell necroinflammatory score, Ishak fibrosis score, total hepatic HBV DNA, and HBe Ag loss at week 48).RESULTS: Overall, 305 patients(ETV = 159; LAM = 146) of ETV-022 had paired baseline and week 48 liver biopsies with evaluable measurements for hepatic HBV ccc DNA and total hepatic HBV DNA, and were included in this analysis. Baseline demographics and disease characteristics were comparable between the two arms. After 48 wk, ETV resulted in significantly greater reductions in hepatic HBV ccc DNA [-0.9 log10 copies/human genome equivalent(HGEq) vs-0.7 log10 copies/HGEq; P = 0.0033] and total hepatic DNA levels(-2.1 log10 copies/HGEq vs-1.6 log10 copies/HGEq; P < 0.0001) than LAM. Virologic, biochemical, and histologic response rates at week 48 were also greater with ETV than with LAM. Baseline HBV ccc DNA levels were positively associated with baseline levels of serum HBV DNA and total hepatic HBV DNA, and negatively associated with HBV genotype F. On-treatment changes in HBV ccc DNA levels were negatively associated with baseline levels of serum HBV DNA and baseline ALT, and were positively associated with on-treatment changes in the levels of serum HBV DNA, total hepatic HBV DNA levels, and ALT, change in Knodell necroinflammatory score, and HBe Ag loss.CONCLUSION: Forty-eight weeks of ETV resulted in greater reductions in ccc DNA and total hepatic HBV DNA than LAM, but long-term therapy may be needed for ccc DNA elimination. | Scott Bowden Stephen Locarnini Ting-Tsung Chang You-Chen Chao Kwang-Hyub Han Robert G Gish Robert A de Man Miao Yu Cyril Llamoso Hong Tang | 2015 | World Journal of Gastroenterology2015，21，15： | 11 |
| 15 | Schistosoma mansoni proteins attenuate gastrointestinal motility disturbances during experimental colitis in mice显示文摘AIM:To investigate the therapeutic effect of Schistosoma mansoni(S.mansoni) soluble worm proteins on gastrointestinal motility disturbances during experimental colitis in mice. METHODS:Colitis was induced by intrarectal injection of trinitrobenzene sulphate(TNBS) and 6 h later,mice were treated ip with S.mansoni proteins.Experiments were performed 5 d after TNBS injection.Inflammationwas quantified using validated inflammation parameters. Gastric emptying and geometric center were measured to assess in vivo gastrointestinal motility.Peristaltic activity of distal colonic segments was studied in vitro using a modified Trendelenburg set-up.Cytokine profiles of T-lymphocytes isolated from the colon were determined by real time reverse transcriptase-polymerase chain reaction. RESULTS:Intracolonic injection of TNBS caused severe colitis.Treatment with S.mansoni proteins significantly ameliorated colonic inflammation after 5 d.TNBS did not affect gastric emptying but significantly decreased the geometric center and impaired colonic peristaltic activity 5 d after the induction of colitis.Treatment with S.mansoni proteins ameliorated these in vivo and in vitro motility disturbances.In addition,TNBS injection caused a downregulation of effector T cell cytokines after 5 d,whereas a S.mansoni protein effect was no longer observed at this time point. CONCLUSION:Treatment with S.mansoni proteins attenuated intestinal inflammation and ameliorated motility disturbances during murine experimental colitis. | Nathalie E Ruyssers Benedicte Y De Winter Joris G De Man Natacha D Ruyssers Ann J Van Gils Alex Loukas Mark S Pearson Joel V Weinstock Paul A Pelckmans Tom G Moreels | 2010 | World Journal of Gastroenterology2010，16，6： | 11 |
| 16 | Dectin- 1 isoforms contribute to distinct Th 1/Th 17 cell activation in mucosal candidiasis显示文摘β 的识别;由 dectin-1 的 -glucans 被显示了调停房间激活, cytokine 生产和许多抗真菌的回答。这里,我们报导在到 Candida albicans 的 mucosal 免疫的 dectin-1 的功能的活动被主人的基因背景影响。Dectin-1 在 C57BL/6,然而并非 BALB/c 老鼠为胃肠、阴道的 candidiasis 的合适的控制被要求;事实上,后者当 dectin-1 不在时显示出增加的抵抗。到感染的 dectin-1-deficient C57BL/6 老鼠的危险性在 IL-17A 和芳基烃受体依赖者 IL-22 生产并且在适应 Th1 回答与缺点被联系。相反, dectin-1-deficient BALB/c 鼠标的抵抗与增加的 IL-17A 和 IL-22 生产并且向提供免疫学的存储器的 Th1/Treg 有免疫力的回答扭曲被联系。迥异的正规 / 不在经典中的 NF-κ dectin-1 下游地表明小径的 B 在二不同老鼠紧张被激活。因此,在抗真菌的 mucosal 免疫的 dectin-1 的网活动依赖于主人的基因背景,它在 dectin-1 发信号之上影响天生的 cytokine 生产和适应 Th1/Th17 房间激活。 | Agostinho Carvalho Gloria Giovannini AntoneUa De Luca Carmen D'Angelo Andrea Casagrande Rossana G Iannitti Giovanni Ricci Cristina Cunha Luigina Romani | 2012 | Cellular & Molecular Immunology2012，9，3： | 10 |
| 17 | Gallstone-related complications after Roux-en-Y gastric bypass:a prospective study显示文摘BACKGROUND: Gastric bypass is a widespread bariatric procedure that carries a high incidence of gallstone formation postoperatively. Controversy exists regarding the importance and consequences of gallstones in these patients. There are surgeons who consider gallstone-related complications after gastric bypass important enough to require routine removal of the gallbladder during gastric bypass (prophylactic cholecystectomy). However, this can lead to increased costs and risks. This study aimed to identify complications related to cholelithiasis after Roux-en-Y gastric bypass (RYGBP). METHODS: This is a prospective observational study of 40 morbidly obese patients free of gallbladder disease. The patients underwent open RYGBP at a public hospital in Brazil from February to October 2007. They were followed up clinically and ultrasonographically at 6 months and 1, 2, and 3 years after surgery. Of the patients, 38 patients were followed up for 3 years. RESULTS: Eleven patients (28.9%) developed cholelithiasis, four (10.5%) experienced biliary pain, and 2 suffered from acute biliary pancreatitis (5.3%). These patients had their gallbladders removed laparoscopically. No patient presented with acute cholecystitis, choledocholithiasis, or bile duct dilation during the follow-up period. There were no deaths. CONCLUSIONS: Gallstone-related complications after RYGBP were relatively common. Some of these complications, like acute pancreatitis, are known to have potentially severe outcomes. It seems reasonable to perform cholecystectomy during gastric bypass in the presence of cholelithiasis or after this procedure if gallstones develop. | Rachid G Nagem Alcino Lázaro-da-Silva Rafael Morroni de Oliveira Valter Garcia Morato | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，6： | 10 |
| 18 | 基于车激响应和灵敏度分析的桥梁结构损伤识别方法研究显示文摘提出了一种利用桥梁结构在车辆荷载作用下在线响应评估结构性损伤的方法。以单元弯曲刚度的变化量为识别指标,基于车桥动力相互作用理论计算车激桥梁响应以及响应对损伤指数的灵敏度,以结构不同状态下的响应残差为约束条件,利用最小二乘法求解灵敏度方程得到各单元的损伤指数,然后通过有限元更新技术和反复迭代,最终实现对桥梁损伤的定位和定量分析。分析了测量噪声和轨道不平顺对损伤识别结果的影响规律。数值算例表明,所提的损伤识别方法对轨道不平顺和量测噪声不敏感,可以利用加速度、速度或者位移响应有效识别桥梁的绝对损伤或相对损伤。 | 战家旺 夏禾 陈上有 De Roeck G | 2011 | 工程力学2011，28，11： | 10 |
| 19 | 汽车用钢的最新研究进展显示文摘为满足提高燃油效率及汽车'轻量化'等方面持续的需求,学术界及工业领域一直都很重视钢铁及其替代材料的研发,这两类材料之间的竞争始终十分激烈。对汽车用钢在北美的研究现状进行了概述,并重点介绍了几种冷轧和热轧汽车用钢的研究进展及其生产情况。新一代先进高强钢的发展将依然令人关注并充满机遇。 | John G Speer David K Matlock Emmanuel de Moor Grant A Thomas 周澍(译) 李晟(校) | 2013 | 世界钢铁2013，，5： | 10 |
| 20 | 酒精摄入、心脏生物标志物和心房颤动风险与不良结局显示文摘酒精摄入和新发心房颤动相关性证据不一,尤其是在低剂量下。该研究评估欧洲队列在整个饮酒范围内酒精摄入、生物标志物和新发心房颤动的关系。方法和结果:在一个以社区为基础的汇集队列中,研究者随访107845人,以评估酒精摄入(酒精种类和饮酒方式)与新发心房颤动的关系。研究者收集经典心血管病危险因素和新发心力衰竭的信息,并检测生物标记物氨基末端脑钠肽前体和高敏肌钙蛋白I。 | 陈嘉睿(译) 练桂丽((审校) Csengeri D Sprünker NA Di Castelnuovo A Niiranen T Vishram-Nielsen JK Costanzo S S derberg S Jensen SM Vartiainen E Donati MB Magnussen C Camen S Gianfagna F L chen ML Kee F Kontto J Mathiesen EB Koenig W Stefan B de Gaetano G J rgensen T Kuulasmaa K Zeller T Salomaa V Iacoviello L Schnabel RB | 2021 | 中华高血压杂志2021，29，2： | 9 |
您所在的机构暂未开通此部分的功能，请联系管理员